letetresgene autoleucel

Cell therapy

Weakdesign only

Evidence outlook · no controlled comparison

NCT05993299 · Neoplasms

The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.

NCT05993299: The study was open-label, nonrandomized, and had no comparator arm, with only 5 participants included in the reported response analysis. Although the primary RECIST 1.1 tumor-response endpoint showed an 80% response rate, the uncontrolled design cannot establish how much benefit was caused by letetresgene autoleucel.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 2 (5)
Myxoid/Round Cell Liposarcoma
NCT02992743 · GlaxoSmithKline
2016-12-06 – 2022-03-22 · Neoplasms
What this study did
Other / comorbidity
NCT03967223 · USWM CT, LLC
2019-12-31 – 2028-07-31 · Neoplasms
What this study did
Phase 1/2 (1)
Phase 1 (2)
Other / comorbidity
NCT03168438 · GlaxoSmithKline
2017-08-18 – 2020-11-05 · Neoplasms
What this study did
NCT02588612 · GlaxoSmithKline
2016-02-01 – 2020-08-10 · Neoplasms
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.